Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Mike Putman EBRheum
3 years 1 month ago
"You won't find IgG4-RD anywhere [in the 2012 Chapel Hill nomenclature], but it is absolutely a vasculitis"
-John Stone
#ACR22 @RheumNow
Dr. Rachel Tate uptoTate
3 years 1 month ago
LILAC study abstracts 0364 and 0365 SLE pts w/ joint and skin activity treated with BIIB059 had consistent improvements vs PBO. More to come! #ACR22 @RheumNow https://t.co/WPl3tol7v9 and https://t.co/8cyrI3W9rD https://t.co/5W4KMOHHEA
Janet Pope Janetbirdope
3 years 1 month ago
Need to know! Wigley says ‘each organ system has unique properties’ so ex Rx of skin may not help vasculopathy or #SSc renal crisis Rx is ACEi vs CCB in #Raynauds. 1 drug won’t be sufficient in complex diseases #13S114 #ACR22 #ACRBest @RheumNow #ClinicalPearl https://t.co/S8fHi7dFoD
David Liew drdavidliew
3 years 1 month ago
MoA qu in GCA:
Is one JAKi better?
lab in tofa
proof-of-concept in bari
clinical trial in upa
@MdWarrington: unclear if any diff clinically
GM-CSF vs IL-17?
Maria Cid: lots of redundancy in immune system
blocking one pathway, escalation of another?
we will see
#ACR22 @RheumNow
Julian Segan JulianSegan
3 years 1 month ago
Combined pulmonary HTN and ILD seen in 7% in large scleroderma database. Unsurprisingly, survival worse then PAH/ILD alone. HAQ also worse in this group.
@RheumNow @earlyARA #ACR22 ABST1058
https://t.co/Jr58wVLC31 https://t.co/UCjKuJB1ev
Dr. Rachel Tate uptoTate
3 years 1 month ago
Abs 0359 TULIP-1&2 data showed nearly 10% of anifrolumab-treated pts achieved remission, suggesting that DORIS response is attainable. #ACR22 @RheumNow https://t.co/laPwd0KpSa https://t.co/6LZ1WLrc97
Mike Putman EBRheum
3 years 1 month ago
Great scientific talk by John Stone, IgG4-RD should be a considered a variable-vessel disease, much like Behcet's and Cogan's syndrome
I had not viewed it from that perspective; adding it to the list! Series of patietns w/coronary involvement esp interesting
#ACR22 @RheumNow https://t.co/JUayLOTnSB
Janet Pope Janetbirdope
3 years 1 month ago
Slow pruning of Pulmonary arteries occurs way before we detect #PAH pulmonary hypertension in #scleroderma #SSc 13S114 lecture by Fred Wigley. Screen but need data re earlier Rx before Dx of PAH. May be assoc w anticentrome and +++ telangiectasia @RheumNow #ACR22 https://t.co/AgnIMYFKjB
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR22 Abstr#1464 Press Release #lupus. Should we worry of pts without nephritis & low grade proteinuria UPCR >0.2 & <0.5? A cohort study showed 50% progressed to =>0.5 at 2 yrs & 11% renal biopsy +ve. Important to monitor UPCR. Need biomarkers for this At-Risk @RheumNow #ACRBest https://t.co/eOODUynvP4
Catherine Sims, MD DrCassySims
3 years 1 month ago
PCP docs managing AS?
Abstract #0078
🧑⚕️ Assessed differences in management between PCP and rheumatologists
💉RHU prescribed more biologics
💊PCP prescribed more opiate and non-opiate pain medications
💊PCP did not often prescribe csDMARDs or biologics
#ACR22 @RheumNow
Julian Segan JulianSegan
3 years 1 month ago
1918 influenza brought us proper design of vaccine trials as well as discovery of the influenza virus
@RheumNow #ACR22 @HRheuminations https://t.co/RlNXSWMWBz
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
Please see my short review on new data and progress of BAFF/APRIL inhibition in #lupus #SLE presented at #ACR22 @RheumNow https://t.co/pqxdAcMH5e https://t.co/9IIrxVZvGe
Eric Dein ericdeinmd
3 years 1 month ago
Ab0575 #ACR22 MI/CVA in Osteoporosis Pts on DEN/ ZOL, L Spangler
DEN pts more likely CKD, adjusted analysis
At 36 mos, risk for Den vs Zol in 2 database claims:
- MI: 0.97, 1.22 (0.8-1.7)
- CVA: 0.9 (0.6-1.2), 1.0
No incr. risk identified with Den vs Zol in MI or CVA
@RheumNow https://t.co/hgyG1ZmFLT
Julian Segan JulianSegan
3 years 1 month ago
Other potential mechanisms for survival selection against the plague via MHC presentation to CD8 T cells. May be associated with SpA/HLA B27
@RheumNow @HRheuminations #ACR22 #rheuminations https://t.co/Rv117B4IYp
Poster Hall